DAVID ALTSHULER - 24 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
24 Feb 2023
Net transactions value
-$2,366,256
Form type
4
Filing time
28 Feb 2023, 15:40:33 UTC
Previous filing
22 Feb 2023
Next filing
11 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $1,147,806 -3,970 -9.9% $289.12 36,276 24 Feb 2023 Direct
transaction VRTX Common Stock Sale $1,044,368 -3,636 -10% $287.23 32,640 27 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $86,622 -300 -0.92% $288.74 32,340 27 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $87,459 -302 -0.93% $289.60 32,038 27 Feb 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.80 to $287.72).
F4 Open market sales reported on this line occurred at a weighted average price of $288.74 (range $288.42 to $289.37).
F5 Open market sales reported on this line occurred at a weighted average price of $289.60 (range $289.49 to $289.65).